期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

那格列奈及其类似物的研究进展 被引量：6

Progress in research of nateglinide and its analogues
下载PDF
导出
摘要 那格列奈是一种新型的治疗 2型糖尿病的口服药物 ,它能够被快速吸收和消除 ,从而使膳食时的血糖得到生理性控制。本文综述了那格列奈的药效学性质及其构效关系研究 ,并对它的类似物瑞格列奈、KAD 12 2 9和利用那格列奈设计新型的降血糖分子进行了介绍。 Nateglinide is a novel oral hypoglycemic agent used in type 2 diabetes.It is absorbed and eliminated in short time and made the blood glucose of diet in physiological control.The pharmacodynamic of nateglinide and its structure activity relationship are reviewed.Its two analogues of repaglinide and KAD 1229 and hybrid compound of nateglinide are also introduced.
作者 潘满根 刘克良 仲伯华
机构地区 军事医学科学院毒物药物研究所
出处 《中国新药杂志》 CAS CSCD 北大核心 2002年第8期585-587,共3页 Chinese Journal of New Drugs
关键词 研究进展 那格列奈 2型糖尿病 构效关系 瑞格列奈 KAD-1229 nateglinide type 2 diabetes mellitus structure activity relationship repaglinide KAD 1229
分类号 R977.15 [医药卫生—药品] R587.105 [医药卫生—内分泌]
  • 相关文献

参考文献29

  • 1Lider TR.FDA approves nateglinide for treatments of type 2 diabetes[J].Am J Health Syst Pharm,2001,58(4)∶285,288.
  • 2Kahn SE,Porte D.Islet dysfunction in non-insulin-dependent diabetes mellitus[J].Am J Med,1988,85∶4-8.
  • 3Girard J.Role of insulin resistance in type 2 diabetes[J].Diabetes Metab,1994,20∶330-336.
  • 4Perfetti R,Mathur R,Egan JM.New insulin secretagogues for the treatment of type 2 diabetes[J].Dis Manage Clin Outcome,1998,1∶129-135.
  • 5Hu S,Wang S,Fanelli F,et al.Pancreatic β-cell KATP channels activity and membrane-binding studies with nateglinide:a comparison with sulfonylureas and repaglinide[J].J Pharmacol Exp Ther,2000,293(2)∶444-452.
  • 6Fujitani S,Ikenoue T,Kiyoshi M,et al.Somatostain and insulin secretion due to common mechanisms by a new hypoglycemic agent,A-4166, in perfused rat pancreas[J].Metabolism,1996,45∶184-189.
  • 7Malaiss WJ.Insulinotropic action of meglitinide analogue:modulation by an activator of ATP-sensitive K+ channels and high extracelluar K+ channels and high extracelluar K+ concentrations[J].Pharmacol Res,1995,32(3)∶111-114.
  • 8Kikuchi M.Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycemic agents,NN-623 and A-4166[J].Diabet Med,1996,13∶131-135.
  • 9Choudhury S,Hirschberg Y,Filkipek R,et al.Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis[J].J Clin Pharmacol,2000,40(6)∶634-640.
  • 10Takesada H, Matsuda K,Ohtake R,et al.Structure determination of metabolites isolated from urine and bile after administration of AY4166,a novel D-phenylalanine-derivative hypoglycemic agent[J].Bioorg Med Chem,1996,4∶1771-1781.

同被引文献73

  • 1王少真,徐延光,史亚男.马来酸罗格列酮联合小剂量二甲双胍和那格列奈改善胰岛素抵抗对糖尿病前期伴非酒精性单纯性脂肪肝的逆转作用[J].中国全科医学,2009,12(9):729-731. 被引量：14
  • 2顾萍,李语如.那格列奈及其片剂中L-异构体的HPLC测定[J].中国医药工业杂志,2004,35(8):486-487. 被引量：5
  • 3李桃荣,宁尚侠.那格列奈治疗2型糖尿病的临床观察[J].中国医院药学杂志,2005,25(9):865-866. 被引量：9
  • 4邓燕,蒋欢妹,谢维跃,陶德良.那格列奈的合成工艺研究[J].精细化工中间体,2006,36(3):19-20. 被引量：9
  • 5Shinkai H, Nishikawa M, Sato Y, et al. N- ( Cyclo-hexylcarbonyl)-D phenylalanines and related compounds :A new class of oral hypoglycemic agents [ J ]. J Med Chem, 1989,32 (7) : 1436-1441.
  • 6Cheng Yong Ke, Li Gang, Huang Changgao. Another novel crystal from of nateglinide[J]. Journal of Nanjing Normal University : Natural Science Edition ,2007,30(2) :51-53.
  • 7Jijakli H, Ulusoy WJ, Malaisse WJ. Dissociation between the potency and reversibile of the insulin tropic action of two meglitinide analoguos[J ]. Pharmacol Res, 1996,34(3/4):105- 108.
  • 8Ohnota H, Koizumi T, Kobayashi M, et al. Novel rapid- and short-acting hypoglycemic agent, a calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolcarbonyl) propionate(KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and glipizide[J ]. J Pharmacol Exp, 1994,269 (2):489 - 495.
  • 9Bell GI, Santerre RF, Mullenhach GT. Hamster preproglucagon contains the sequence of glucagon and related peptides[J ]. Nature, 1983,302(5910) :716 - 718.
  • 10Villhauer EB,Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino] acetyl ]-2-cyano-( S )-pyrrolidine: a potent,selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties [ J ]. J Med Chem, 2003, 46(13) :2774 - 2789.

引证文献6

二级引证文献28

中国新药杂志
2002年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部